本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHANGHAI and NANJING, China and SAN JOSE, Calif., Dec. 12, 2023 /PRNewswire/ -- IASO biotechnology ("IASO Bio"), a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, today announced the latest analysis results from the FUMANBA-1 study of Equecabtagene Autoleucel for the treatment of multiple myeloma in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting. The presentation highlights the characteristics and efficacy of fully human BCMA-targeting CAR-T (Equecabtagene Autoleucel) on multiple myeloma patients who had sustained minimal residual disease (MRD) negativity after receiving treatment. Oral Presentation Overview Presentation Title: Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1 Session Date and Time: Monday, December 11, 2023, 11:30 AM (San Diego) Publication Number: 761 Presenter: Dr. Jue Wang, Associate Professor, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology The presentation is based on a post-hoc analysis of the FUMANBA-1 study. The FUMANBA-1 Study(Registration No.: NCT05066646) is a Phase Ib/II, single-arm, multicenter study to assess the efficacy and safety of the investigational drug Equecabtagene Autoleucel (IASO R&D code: CT103A, Innovent R&D code: IBI326), a fully human CAR-T cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM) who have received 3 or more lines of treatment. As of December 31, 2022, with a median follow-up of 18.07 months, deep and sustained responses were observed in 103 evaluable patients. Among these patients, the overall response rate (ORR) was 96.1%, and the stringent complete response/complete response (sCR/CR) rate was 77.7%. Among subjects without prior CAR-T therapy, the ORR reached 98.9%, the sCR/CR rate reached 82.4%, and the 12-month progression-free survival (PFS) rate was 85.5%. Minimal residual disease (MRD) negativity rate is 94.2% in the total evaluable patients, and all patients who achieved CR or above were MRD negative. The median time to achieve MRD negativity was 15 days, with 80.8% of patients remaining MRD negative at 12 months post infusion. In addition, Equecabtagene Autoleucel could persist in the body for an extended period of time the median duration was 307.5 days. 12 months after infusion, 50% of patients had a vector copy number (VCN) above the lower limit of detection; and 24 months after infusion, VCN could still be detected in 40% of the patients. Based on the descriptive analysis, patients receiving eque-cel achieved MRD negativity irrespective of cytogenetics status，extramedullary disease status，number of prior lines of therapy，and performance status. It suggests that eque-cel as immune cell therapy showed strong killing effect to myeloma cells without affecting by these factors. In the FUMANBA-1 study, 90 RRMM patients without prior CAR-T therapy were evaluable for MRD test at 10-5. The results showed: (1) An important prognostic factor for progression-free survival (PFS) in patients with RRMM treated with Equecabtagene Autoleucel is sustained MRD negativity: When comparing the PFS of patients in different MRD negative duration groups, those in the ≥ 6 months and ≥ 12 months group were significantly better than those in the < 6 months group. This was particularly true for those in the ≥ 12 months MRD negative duration group. (2) There is a correlation between the persistence of CAR-T cells and sustainability of MRD negativity after infusion of Equecabtagene Autoleucel: Overall, there is a positive correlation between the two. This was particularly evident in subgroup analysis. The Triple-class exposure subgroup, the previous autologous transplantation treatment history subgroup, the high-risk cytogenetic abnormality subgroup, etc., showed a moderate to strong positive correlation between the persistence of CAR-T cells (VCN persistence) after infusion of Equecabtagene Autoleucel and the duration of MRD negativity. The correlation may become more significant in the future with longer term follow-up data, which could further reveal the positive correlation between long-term survival of CAR-T cells and long-term maintenance of MRD negativity. "Studies have shown MRD is a biomarker that affects the long-term survival of RRMM patients. It's necessary to maintain MRD negativity to improve the prognosis of RRMM patients and extend PFS. Equecabtagene Autoleucel has overcome two difficulties faced by traditional therapies in maintaining MRD negativity. First, it has increased the proportion of patients with MRD-negative persistence past 12 months from less than 10% to 80%. Second, only one-time infusion is needed to achieve sustainable MRD negativity. Traditional therapies require continuous medication to maintain MRD negativity, and once medication is stopped, patients face the risk of relapse. Patients who do not stop the medication will be facing the potential risk of inducing drug-resistant clones. Long-term medication and complex therapies increase direct treatment costs, seriously affect patients' quality of life. The adverse effects caused by long term treatment also increase indirect costs to patients and their families. With its outstanding long-term persistence in the body, Equecabtagene Autoleucel can achieve lasting and deep remission in RRMM patients who have failed multiple lines of treatment. We expect that it will give more patients the hope of a cure," said principal investigators Professor Lu-gui Qiu, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, and Professor Chunrui Li, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology. About IASO Bio IASO Bio is a biopharmaceutical company engaged in the discovery and development of novel cell therapies and biologics for oncology and autoimmune diseases. IASO Bio possesses comprehensive capabilities spanning the entire drug development process, from early discovery to clinical development, regulatory approval, and commercial production. The pipeline in the company includes a diversified portfolio of over 10 novel products, including Equecabtagene Autoleucel (a fully human BCMA CAR-T injection). Equecabtagene Autoleucel received New Drug Application (NDA) approval from China's National Medical Products Administration (NMPA) and U.S. FDA IND approval for the treatment of RR MM. Leveraging its strong management team, innovative product pipeline, GMP production, as well as integrated manufactural and clinical capabilities, IASO aims to deliver transformative, curable, and affordable therapies that fulfil unmet medical needs to patients in China as well as around the world. For more information, please visit http://www.iasobio.com or www.linkedin.com/company/iasobiotherapeutics. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, including TYVYT® (Sintilimab Injection), BYVASDA® (Bevacizumab Injection), SULINNO® (Adalimumab Injection), HALPRYZA® (Rituximab Injection), Pemazyre® (Pemigatinib Oral Inhibitor), Olverembatinib, Cyramza® (Ramucirumab Injection), Retsevmo® (Selpercatinib Capsules ), FUCASO® (Equecabtagene Autoleucel Injection) and SINTBILO® (Tafolecimab Injection).Additionally, we have 2 assets are under NMPA NDA review, 5 assets are in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage. Innovent has also entered into more than 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives. Contact: IASO BioMedia: pr@iasobio.comInvestors: ir@iasobio.com Innovent BiologicsMedia:pr@innoventbio.com +86 512-6956 6088Investors:ir@innoventbio.com+86 512-6956 6088
Polymetal International plc Results of GM Polymetal International plc (the “Company”) announces that at the General Meeting (“GM”) of the Company which was held on Friday, 8 December 2023, at 10.00 am Astana time (GMT+6), all resolutions proposed by the Directors in the Notice of the GM dated 23 November 2023 were duly passed with the results as stated below. Voting results Resolution* Vote type Voted Voted % % of Issued Share Capital** 01. BUYBACK APPROVAL For 159,826,831 89.34 33.74 Against 18,011,923 10.07 3.80 Votes Withheld 1,067,769 0.60 0.23 02. ARTICLES OF ASSOCIATION For 159,829,167 89.33 33.74 Against 18,011,264 10.07 3.80 Votes Withheld 1,075,925 0.60 0.23 03. TREASURY SHARES For 159,874,070 89.36 33.75 Against 17,972,264 10.05 3.79 Votes Withheld 1,070,022 0.60 0.23 * Resolutions 1 and 2 are special resolutions and resolution 3 is an ordinary resolution.** The Company holds 41,614,678 ordinary shares in treasury, which do not enjoy any voting or economic rights. Therefore, the total number of voting rights in the Company as of the GM date is 473,645,141. With these resolutions passed, the Exchange Offer announced on 23 November 2023 is approved. Further details of the Exchange Offer can be found in the combined shareholder circular and notice of General Meeting (the "Circular") and press release published on 23 November 2023. The documents are available at the link: https://www.polymetalinternational.com/en/investors-and-media/shareholder-centre/general-meetings/. The Company is currently finalising arrangements with Nominated Brokers. Details of the Nominated Brokers, exchange instructions and further course of actions will be announced in due course. Background On 3 June 2022, the EU imposed sanctions on NSD, which effectively blocked the operations between Euroclear and NSD. As a result of such sanctions, prior to the First Exchange Offer, Shareholders holding approximately 22% of the Company's issued share capital were unable to take part in any corporate actions of the Company and/or receive dividends. This prevented the Company from being able to carry out certain corporate actions with the involvement of a significant part of its shareholder base. On 22 September 2022, the Board announced the First Exchange Offer to exchange certain shares eligible under the terms of such offer for newly issued shares. A total of 41,614,678 Shares (or approximately 8% of the total number of voting rights in the Company) were repurchased by the Company under the First Exchange Offer which was completed on 11 October 2023. The Company now holds 41,614,678 Shares in treasury, which, according to AIFC Law, do not enjoy any voting or economic rights. Approximately 14% of the Company's Shares were not eligible to participate in the First Exchange Offer although were affected, and therefore continue to be impacted by the restrictions imposed even though the shareholders themselves might not be subject to an asset freeze insofar as the Company is aware. As a result, the Company continues to be prevented from carrying out certain corporate actions with the involvement of a significant part of its shareholder base. On 7 August 2023, the Company announced the successful completion of the re-domiciliation of the Company from Jersey to the AIFC. As a result of the re-domiciliation, certain restrictions which previously prevented the First Exchange Offer from being addressed to Eligible Shareholders no longer apply. On 23 November 2023, the Company announced its intention to conduct the Second Exchange Offer to tender Eligible Shares for exchange in consideration for the issue of Exchange Shares on a one-for-one basis. Timetable Announcement of results of General Meeting / Exchange Offer opens 11 December 2023 Notification or announcement of process to accept and adhere to the Buyback Agreement From time to time between 8 December 2023 and 31 October 2024 Announcement of the results of each Settlement Date of a Tranche of Exchange Shares From time to time between 1 January 2024 and 1 November 2024 Last time and date for Exchange Shares to be transferred from the Nominated Broker to the Company Securities Account 30 September 2024 Settlement Date of the last Tranche of Exchange Shares / Exchange Offer closes 31 October 2024 Announcement of the final results of the Exchange Offer On or before 1 November 2024 The above times and/or dates may be subject to change by the Company and in the event of any such change, the revised times and/or dates will be notified to Shareholders by an announcement through the Company website or as otherwise may be required under the AIFC Laws and the AIX Business Rules. Unless otherwise defined herein, defined terms have the same meaning as defined in the Circular. Copies of all the above documents are also available on the Company's website at https://www.polymetalinternational.com/en/investors-and-media/shareholder-centre/general-meetings/. Enquiries Investor Relations Media Evgeny Monakhov +44 20 7887 1475 (UK) Kirill Kuznetsov +7 7172 47 66 55 (Kazakhstan) ir@polymetalinternational.com Yerkin Uderbay +7 7172 47 66 55 (Kazakhstan) media@polymetal.kz FORWARD-LOOKING STATEMENTS This release may include statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements speak only as at the date of this release. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “targets”, “believes”, “expects”, “aims”, “intends”, “will”, “may”, “anticipates”, “would”, “could” or “should” or similar expressions or, in each case their negative or other variations or by discussion of strategies, plans, objectives, goals, future events or intentions. These forward-looking statements all include matters that are not historical facts. By their nature, such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company’s control that could cause the actual results, performance or achievements of the company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the company’s present and future business strategies and the environment in which the company will operate in the future. Forward-looking statements are not guarantees of future performance. There are many factors that could cause the company’s actual results, performance or achievements to differ materially from those expressed in such forward-looking statements. The company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. The copyright of this article belongs to the original author/organization. The current content only represents the author's point of view, and has nothing to do with the position of LongPort. The content is for investment reference only and does not constitute any investment advice. If you have any questions or suggestions about the content services provided by LongPort, please contact us.
Hollysys Board has unanimously approved Ascendent's all cash offer at 42% premium to the unaffected price as of 23 August 2023 Agreement marks culmination of formal sale process conducted by Special Committee of independent directors BEIJING, Dec. 11, 2023 /PRNewswire/ -- Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company") today announced that it has reached an agreement to be acquired by Ascendent Capital Partners ("Ascendent"), an international private investment firm headquartered in Hong Kong. The acquisition, which concludes a months-long sale process, will be completed through an all-cash transaction valued at approximately US$1.66bn. According to the terms of the agreement, Ascendent will acquire all outstanding shares of Hollysys that it does not currently own for US$26.50 per share in cash. This price represents a premium of 42% to the unaffected price of US$18.66 as of August 23, 2023. The Board of Directors of Hollysys (the "Board"), upon the unanimous recommendation of the Special Committee of independent directors, has given its unanimous approval for the transaction. Today's agreement enables Hollysys' shareholders to realize substantial cash value at a significant premium to the Company's recent trading price. Additionally, the ability of Ascendent to secure reputable funding sources and execute the transaction expeditiously further enhances the attractiveness of the deal. This agreement marks the successful culmination of a formal sale process that was part of a review of various strategic options to maximize value for shareholders, including continued execution of the current strategic plan. A sale was determined to provide maximum value discovery to realize the highest value for shareholders. The Board formed the Special Committee of independent directors on October 2, 2023 to run the sale process with the assistance of external advisors. Throughout the process, the Special Committee engaged in extensive discussions with multiple credible offerors who expressed interest in acquiring the Company and a number of buyers participated in such sale process. Certain transaction details The deal will be subject to shareholder approval by the Company and certain closing conditions, including customary regulatory approval. Advisors Deutsche Bank AG, Davis Polk & Wardwell, Mourant Ozannes (Hong Kong) LLP, and Haiwen & Partners are serving as advisors to Hollysys. Ascendent is advised by Morrison & Foerster LLP, Appleby and Zhong Lun Law Firm. About Hollysys Automation Technologies Ltd. Hollysys is a leading automation control system solutions provider in China, with overseas operations in eight other countries and regions throughout Asia. Leveraging its proprietary technology and deep industry know-how, Hollysys empowers its customers with enhanced operational safety, reliability, efficiency, and intelligence which are critical to their businesses. Hollysys derives its revenues mainly from providing integrated solutions for industrial automation and rail transportation. In industrial automation, Hollysys delivers the full spectrum of automation hardware, software, and services spanning field devices, control systems, enterprise manufacturing management and cloud-based applications. In rail transportation, Hollysys provides advanced signaling control and SCADA (Supervisory Control and Data Acquisition) systems for high-speed rail and urban rail (including subways). Founded in 1993, with technical expertise and innovation, Hollysys has grown from a research team specializing in automation control in the power industry into a group providing integrated automation control system solutions for customers in diverse industry verticals. As of June 30, 2023, Hollysys had cumulatively carried out more than 45,000 projects for approximately 23,000 customers in various sectors including power, petrochemical, high-speed rail, and urban rail, in which Hollysys has established leading market positions. About Ascendent Capital Partners Ascendent Capital Partners, headquartered in Hong Kong, is a private equity investment management firm managing assets for global institutional investors, including sovereign wealth funds, endowments, pensions and foundations. Ascendent has successfully led and executed a large number of innovative and ground-breaking private equity investments, generating strong risk-adjusted returns for investors and business growth for our portfolio companies. Ascendent has established a consistent track record in providing advice and solution capital to entrepreneurs, business owners and management teams, building long-lasting relationships through in-depth collaboration. For additional information about Ascendent, please visit Ascendent's website at www.ascendentcp.com. Safe Harbor Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company; growth in financial and operational performance of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident," or similar expressions involve known and unknown risks and uncertainties. Such forward-looking statements, based upon the current beliefs and expectations of Hollysys' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. Contact Information Company Contact:Hollysys Automation Technologies Ltd.www.hollysys.com +8610-5898-1386investors@hollysys.com Media Contacts (Hong Kong and New York):Brunswick Grouphollysys@brunswickgroup.com Daniel Del Re (Hong Kong)ddelre@brunswickgroup.com +852 9255 5136 Libby Lloyd (New York)llloyd@brunswickgroup.com +1 347 283 3871
Inovalon ONE® Platform seamlessly aggregates, standardizes, and analyzes diverse data to gain meaningful insights, support evidence-based decision-making, and offer data security and privacy. SAN ANTONIO, Dec. 11, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare analytics and real-world evidence (RWE) information technology solutions industry and, based on its analysis, recognizes Inovalon with the 2023 North American Product Leadership Award. The cloud-based software-as-a-service (SaaS) provider empowers healthcare organizations with data-driven insights to improve clinical, operational, and financial performance. Through the Inovalon ONE® Platform and its Insights solutions, Inovalon supports payers, providers, pharmacies, and life sciences organizations using real-world data (RWD) and advanced analytics to enhance healthcare outcomes and economics. The cloud-based Inovalon ONE Platform provides SaaS solutions leveraging the company's national-scale connectivity, real-time primary source data, and advanced analytics to provide actionable insights that inform and expedite patient care and business strategies. Using Inovalon's MORE2 Registry®, the nation's largest healthcare dataset originating from longitudinally matched and primary source data, the platform helps achieve data integration, compliance, and security. Additionally, Inovalon's subject matter expertise, vast dataset, and robust data governance help enable artificial intelligence (AI) and machine learning (ML) capabilities to automate workflows, identify and address care gaps, and support its partnerships with technology companies like AWS. Payers, providers, pharmacies, and life sciences organizations can use tailored cloud solutions on the Inovalon ONE Platform to seamlessly aggregate, standardize, and analyze diverse or siloed data to gain meaningful insights and support evidence-based decision making: Inovalon Data Cloud harnesses diverse, longitudinally linkable healthcare data to accelerate healthcare research for life sciences organizations and enable the improvement of economics and outcomes for providers, payers, and pharmacies. Inovalon Payer Cloud offers advanced analytics and dynamic business intelligence to support health plans in improving clinical quality metrics, risk score accuracy, value-based care, member and provider engagement, and more. Inovalon Provider Cloud provides a user-friendly, single-sign-on portal for streamlining revenue cycle management, care quality management, and workforce management. Inovalon Pharmacy Cloud facilitates pharmacy operations and enhances clinical performance through real-time data exchange, automated processing, and electronic decision support. Ojaswi Rana, best practices research analyst at Frost & Sullivan, observed, "Inovalon's best practices transform data into actionable insights through tailored solutions while adapting to market demands and evolving toward innovative SaaS offerings." Inovalon's unique access to extensive and longitudinally linked healthcare datasets positions it as a fundamental framework for innovative solutions, differentiating it in the industry. Its distinct advantage is its collaboration across payer, provider, specialty pharmacy, and life sciences domains, allowing it to effectively utilize data and analytics to address emerging trends in targeted medicine, gene therapy, and oncology. Inovalon is well-positioned to capitalize on new growth opportunities, cementing its position in the North American healthcare analytics and RWE IT solutions space. "The Inovalon ONE Platform seamlessly aggregates, standardizes, and analyzes diverse healthcare data from electronic health records and claims data to provide payers, pharmacies, providers, and life sciences organizations with evidence-based insights for better patient care and decision-making. The company remains a trusted partner, earning a reputation for offering the best healthcare analytics and RWE IT solutions," added Unmesh Lal, research director for Healthcare & Lifesciences at Frost & Sullivan. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry. About Frost & SullivanFor six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. About InovalonInovalon is a leading provider of cloud-based software solutions empowering data-driven healthcare. The Inovalon ONE® Platform brings together national-scale connectivity, real-time primary source data access, and advanced analytics into a sophisticated cloud-based platform empowering improved outcomes and economics across the healthcare ecosystem. The company's analytics and capabilities are used by nearly 20,000 customers supporting more than 50,000 sites of care, and are informed by the primary source data of more than 79 billion medical events across one million physicians, 654,000 clinical settings, and 375 million unique patients. For more information, visit www.inovalon.com. Contact:Ashley WeinkaufP: 210-844-2505E: ashley.weinkauf@frost.com Nick Panayi for InovalonChief Marketing Officermedia@inovalon.com
Adams brings decades of financial experience and industry knowledge to leading brokerage NEW YORK, Dec. 11, 2023 /PRNewswire/ -- Webull, a leading commission-free trading platform with over 40 million downloads globally, today announced the appointment of Arianne Adams as the company's Chief Strategy Officer and Head of Derivatives. In this role, she will report to Webull Financial's CEO Anthony Denier and work closely with the leadership team to oversee company growth and deliver on Webull's mission of making investing more accessible for all. "As a seasoned financial markets and market structure professional with a robust understanding of exchange management and broker-dealer execution, Arianne brings a unique skillset to the Webull team," said Denier. "Webull has quickly become a leading retail investing platform and being able to hire an industry leader like Arianne is proof of how far we have come. We look forward to welcoming Arianne to the team and leveraging her deep industry knowledge to provide best-in-class products to our clients." Adams most recently served as Senior Vice President, Head of Derivatives and Global Client Services at Cboe Global Markets, Inc. where she was responsible for day-to-day operations of the options and futures business. She also led initiatives to identify and educate new investors and expand the use of Cboe's proprietary products globally. Adams has also held senior positions at Goldman Sachs, Capstone Investment Advisors and Merrill Lynch. "I am thrilled to be joining an organization with a vision that closely aligns with my values of educating investors and providing them with advanced trading tools to execute their investment strategies," said Adams. "I am excited to help Webull continue to expand access globally to meet growing customer demand." Adams is well respected in the financial community, having served on several industry committees including the Listed Options Market Structure Committee, CFTC Global Market Structure Subcommittee and STA Options Committee. She attended Pennsylvania State University, where she earned a B.S. in Finance, Minor in Economics and was co-captain of the school's varsity women's swimming team. For more information on Webull and its offerings, please visit www.webull.com. About WebullBrokerage services are offered through Webull Financial LLC ("Webull Financial"), an SEC-registered broker-dealer and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Investment advisory services are offered by Webull Advisors LLC ("Webull Advisors"), a Securities and Exchange Commission (SEC) registered investment adviser. Webull Financial and Webull Advisors are affiliates. All investing is subject to risk, including the possible loss of the money you invest. Neither entity guarantees profits or protection from losses.
SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"), of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has renewed its service agreement (the "Agreement") with Beijing Public Health Foundation ("BPHF"), a non-profit organization dedicated to enhancing Chinese citizens' health through public welfare initiatives and aid programs. Pursuant to the Agreement, Zhongxin and BPHF extended its partnership to work together on a patient aid project (the "Project") to provide medication assistance services for cancer patients. The Project offers free Doxorubicin Hydrochloride Liposome Injections to low-income patients with breast cancer, lymphoma, Kaposi's sarcoma, ovarian cancer, osteosarcoma, and myeloma based on their needs. The Project aims to ensure patients to have longer lasting and more effective medical treatments with less financial burden. The Project operates through over 300 hospitals and 100 pharmacies, where qualified cancer patients after an assessment can receive their medications for free. To date, the Project has been in operation for three years, serving over 6,000 patients and donating more than 22,000 doses of medication. Under the supervision and guidance of BPHF, Zhongxin, leveraging its self-developed patient assistance program technical service platform, is responsible for providing staff with training and daily operation management, maintaining the project website, management for patients, and monitoring and analyzing project progress. These efforts aim to standardize the workflow and enhance the operational efficiency of the Project. Additionally, the platform also performs information management for Project participants, such as hospitals and pharmacies, to improve operational efficiency and accuracy. With the rising incidence of cancer and prolonged life expectancy brought by new technologies, the cost of innovative medications and long-term treatments has intensified financial burden on patients. Zhongchao believes that the Project encourages and supports patients in need to adhere to sustained treatments with significant therapeutic effects and less financial burden on families. Zhongchao remains committed to leveraging its service capabilities and experience in enhancing treatment efficiency and quality of life for cancer patients. About Zhongchao Inc. Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It consolidates the financial results of a variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, and its subsidiaries (the "PRC operating entities") through a series of contractual arrangements. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their "MDMOOC" platform (www.mdmooc.org), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at http://izcmd.com. Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: At the Company: Pei Xu, CFOEmail: xupei@mdmooc.orgPhone: +86 13901629242 Investor Relations: Sherry Zheng Weitian Group LLCEmail: shunyu.zheng@weitian-ir.comPhone: +1 718-213-7386
A12 藝術空間
investors
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
